Stock Analysis

Jiangsu Yuyue Medical Equipment & Supply Co., Ltd.'s (SZSE:002223) Shares Lagging The Market But So Is The Business

SZSE:002223
Source: Shutterstock

Jiangsu Yuyue Medical Equipment & Supply Co., Ltd.'s (SZSE:002223) price-to-earnings (or "P/E") ratio of 12.9x might make it look like a strong buy right now compared to the market in China, where around half of the companies have P/E ratios above 32x and even P/E's above 59x are quite common. Although, it's not wise to just take the P/E at face value as there may be an explanation why it's so limited.

Jiangsu Yuyue Medical Equipment & Supply certainly has been doing a good job lately as it's been growing earnings more than most other companies. One possibility is that the P/E is low because investors think this strong earnings performance might be less impressive moving forward. If not, then existing shareholders have reason to be quite optimistic about the future direction of the share price.

Check out our latest analysis for Jiangsu Yuyue Medical Equipment & Supply

pe-multiple-vs-industry
SZSE:002223 Price to Earnings Ratio vs Industry April 3rd 2024
If you'd like to see what analysts are forecasting going forward, you should check out our free report on Jiangsu Yuyue Medical Equipment & Supply.

Is There Any Growth For Jiangsu Yuyue Medical Equipment & Supply?

The only time you'd be truly comfortable seeing a P/E as depressed as Jiangsu Yuyue Medical Equipment & Supply's is when the company's growth is on track to lag the market decidedly.

If we review the last year of earnings growth, the company posted a terrific increase of 113%. The latest three year period has also seen an excellent 73% overall rise in EPS, aided by its short-term performance. Therefore, it's fair to say the earnings growth recently has been superb for the company.

Turning to the outlook, the next year should bring diminished returns, with earnings decreasing 16% as estimated by the eight analysts watching the company. That's not great when the rest of the market is expected to grow by 37%.

In light of this, it's understandable that Jiangsu Yuyue Medical Equipment & Supply's P/E would sit below the majority of other companies. However, shrinking earnings are unlikely to lead to a stable P/E over the longer term. There's potential for the P/E to fall to even lower levels if the company doesn't improve its profitability.

The Bottom Line On Jiangsu Yuyue Medical Equipment & Supply's P/E

We'd say the price-to-earnings ratio's power isn't primarily as a valuation instrument but rather to gauge current investor sentiment and future expectations.

As we suspected, our examination of Jiangsu Yuyue Medical Equipment & Supply's analyst forecasts revealed that its outlook for shrinking earnings is contributing to its low P/E. At this stage investors feel the potential for an improvement in earnings isn't great enough to justify a higher P/E ratio. Unless these conditions improve, they will continue to form a barrier for the share price around these levels.

There are also other vital risk factors to consider and we've discovered 3 warning signs for Jiangsu Yuyue Medical Equipment & Supply (1 shouldn't be ignored!) that you should be aware of before investing here.

If you're unsure about the strength of Jiangsu Yuyue Medical Equipment & Supply's business, why not explore our interactive list of stocks with solid business fundamentals for some other companies you may have missed.

Valuation is complex, but we're helping make it simple.

Find out whether Jiangsu Yuyue Medical Equipment & Supply is potentially over or undervalued by checking out our comprehensive analysis, which includes fair value estimates, risks and warnings, dividends, insider transactions and financial health.

View the Free Analysis

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.